Recent Updates
Recently added Catalysts
ALGS Positive Sentiment

Monotherapy with the Capsid Assembly Modulator ALG-000184 Results in High Viral Suppression Rates in Untreated HBeAg-Positive Subjects with Chronic Hepatitis B Virus Infection

Friday, March 28, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the promising results of monotherapy with the capsid assembly modulator ALG-000184, which has shown high viral suppression rates in untreated HBeAg-positive subjects with chronic Hepatitis B virus infection. This development suggests a potential new treatment avenue for managing chronic HBV infections. The study highlights the efficacy of ALG-000184, indicating its significance in the ongoing fight against Hepatitis B.
Price reaction · baseline $8.9701 (2025-03-28T19:58:00.000Z) · hit during market hours · 1 other ALGS headline(s) in the window, move may be shared
day 0 close · peak
+1.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • High viral suppression rates observed in untreated subjects.
  • Monotherapy with ALG-000184 shows promising results.
  • Potential for effective management of chronic Hepatitis B.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+153%
120-day peak, hindsight
Typical move
6.1%
average across 6 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
ALG-055009
Phase 2 · NASH

Full Press Release Details

• About Overview Management Board of Directors
• Science Pipeline Posters & Presentations
• Patients Chronic HBV Infection MASH Clinical Trials Expanded Access Policy
• News & Media Press Releases Presentations & Events
• Investors Overview Stock Stock Quote & Chart Analyst Coverage News & Events News Releases Investor Calendar Financials SEC Filings Quarterly Results Governance Governance Highlights Committee Composition Resources Investor FAQs Email Alerts Contact IR
• Careers
• Overview
• Management
• Board of Directors
• Pipeline
• Posters & Presentations
• Chronic HBV Infection
• MASH
• Clinical Trials
• Expanded Access Policy
• Press Releases
• Presentations & Events
• Overview
• Stock Stock Quote & Chart Analyst Coverage
• News & Events News Releases Investor Calendar
• Financials SEC Filings Quarterly Results
• Governance Governance Highlights Committee Composition
• Resources Investor FAQs Email Alerts Contact IR
• Stock Quote & Chart
• Analyst Coverage
• News Releases
• Investor Calendar
• SEC Filings
• Quarterly Results
• Governance Highlights
• Committee Composition
• Investor FAQs
• Email Alerts
• Contact IR

Frequently Asked Questions

What is ALG-000184?

ALG-000184 is a capsid assembly modulator used in the treatment of chronic Hepatitis B.

What were the results of the study on ALG-000184?

The study reported high viral suppression rates in untreated HBeAg-positive subjects.

Who were the subjects in the ALG-000184 study?

The subjects were untreated individuals with chronic Hepatitis B virus infection.

What does high viral suppression indicate?

High viral suppression indicates the potential effectiveness of a treatment for chronic HBV.

ShareAdd on Google
Tags: ALGS Viatris Investor Conferences Healthcare Hepatitis B chronic HBV ALG-000184 viral suppression biopharma
Last updated: Mar 28, 2025

Biotech snapshot

Cash runway
$30M liquidity · $8M/mo burn
~3 mo
High dilution risk
Lead asset
ALG-055009Phase 2
NASH →

Catalyst track record

+153%
best trade around ALGS's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ALGS.

See every catalyst's timing & PoA →